Kristen Morris

Revised estimates of incidence and risk factors for amyloid related imaging abnormalities (ARIA) in the phase 2 studies of bapineuzumab for mild-to-moderate Alzheimer's disease

E. Liu, S. Salloway, R. Black, 2011, Alzheimer's & Dementia.

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

Nick C Fox, Jerome Barakos, Donatella Tampieri, 2012, The Lancet Neurology.

Clinical Correlates of Amyloid-Related Imaging Abnormalities (ARIA) in Phase 3 Studies of Bapineuzumab in Alzheimer's Disease (AD) (S44.002)

R. Sperling, S. Salloway, C. Dyck, 2013 .